Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2377-2381

  Loprinzi, Charles L ^a   Pisansky, Thomas M ^b   Fonseca, Rafael ^b   Sloan, Jeff A ^b   Zahasky, Katherine M ^b   Quella, Susan K ^b   Novotny, Paul J ^b   Rummans, Teresa A ^b   Dumesic, Daniel A ^b   Perez, Edith A ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CLONIDINE; MEGESTROL ACETATE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; VENLAFAXINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEMALE; HOT FLUSH; HUMAN; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOMNOLENCE; XEROSTOMIA;

EID: 0031859788     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2377     Document Type: Article

References (21)

1. Young RL, Kumar NS, Goldzicher JW: Management of menopause when estrogen cannot be used. Drug 40:220-230, 1990
2. Goldberg RM, Loprinzi CL, O'Fallon JR, et al: Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 12:155-158, 1993
3. Bergmans M, Merkus J, Corbey RS, et al: Effect of bellegal retard on climacteric complaints: A double-blind, placebo-controlled study. Maturitas 9:227-234, 1987
4. Nesheim BI, Saetre T: Reduction of menopausal hot flashes by methyldopa: A double-blind crossover trial. Eur J Clin Pharm 20:413-416, 1981
5. Barton DL, Loprinzi CL, Quella SK, et al: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 16:495-500, 1998
6. Charig CR, Rundle JS: Flushing: Long term side effect of orchiectomy in treatment of prostatic carcinoma. Urology 33:175-178, 1989
7. Loprinzi CL, Goldberg RM, O'Fallon JR, et al: Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J Urol 151:634-636, 1994
8. Loprinzi DL, Michalak JC, Quella SK, et al: Megestrol acetate for the prevention of hot flashes. N Engl J Med 331:347-352, 1994
9. Quella SK, Loprinzi CC, Sloan JA, et al: Long-term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 82:1784-1788, 1998
10. Bronzo MR, Stahl SM: Galactorrhea induced by sertraline Am J Psychiatry 150:1269-70, 1993(letter)
11. Urban RJ, Veldhuis JD: A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women. Am J Obstet Gynecol 164:147-152, 1991
12. Jeffries J, Bezchlibnyk-Butler K, Remington G: Amenorrhea and galactorrhea associated with fluvoxamine in a loxapine-treated patient. J Clin Psychopharmacol 12:296-297, 1992 (letter)
13. Verbeke K, Dhont M, Vandekerckhove D: Clinical and hormonal effects of long-term veralipride treatment in postmenopausal women. Maturitas 10:225-230, 1988
14. Zichella L, et al: Effects of different dopamine agonists and antagonists on postmenopausal hot flushes. Maturitas 8:229-237, 1986
15. Wesel S, Bourguignon RP, Bosuma WB: Veralipride versus conjugated oestrogens: A double-blind study in the management of menopausal hot flushes. Curr Med Res Opin 8:696-700, 1984
16. Vercellini P, Sacerdote P, Trespidi L, et al: Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: A controlled study. Fertil Steril 62:938-942, 1994
17. Vercellini P, Vendola N, Colombo A, et al: Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment. Gynecol Obstet Invest 34:102-104, 1992
18. Melis GB, Gambacciani M, Cagnacci A, et al: Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women. Obstet Gynecol 72:688-692, 1988
19. David A, Don R, Tajchner G, et al: Veralipride: Alternative antidopaminergic treatment for menopausal symptoms. Am J Obstet Gynecol 158:1107-1115, 1988
20. Fioretti P, Cagnacci A, Paoletti AM, et al: Effects of the antidopaminergic drug veralipride on LH and PRL secretion in postmenopausal women. J Endocrinol Invest 12:295-301, 1989
21. Quigley ME, Judd SJ, Gilliland CB, et al: Effects of a dopamine antagonist on the release of gonadotropin and prolactin in normal women and women with hyperprolactinemic anovulation. J Clin Endocrinol Metab 48:718-720, 1979